Frontiers | HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met | Scientific Reports
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
Biomedicines | Free Full-Text | Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment
c-Met inhibitor - Wikipedia
Contemporary Developments in MET-Selective Kinase Inhibitors in Advanced NSCLC
Frontiers | Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
Recent advances in the discovery of small molecule c-Met Kinase inhibitors - ScienceDirect
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors | ACS Medicinal Chemistry Letters
Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition | SpringerLink
Classification of HGF/c-MET Inhibitors. | Download Table
![PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fb34e0b378ab283ee885fb912c61cc28ae8a288b/3-Figure1-1.png "PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar")
PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar
Tivantinib (ARQ 197) | 99.65%(HPLC) | In Stock | c-Met inhibitor
Dictamnine, a novel c-Met inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways - ScienceDirect
Crizotinib is an Orally Active, ATP-Competitive ALK and c-Met inhibitor - Network of Cancer Research
cに応じられた阻害 | c-Met Inhibition
c-Met inhibitor - Wikipedia
HGF-MET inhibitors and potential sites of action. Abbreviations: HGF,... | Download Scientific Diagram
The role of MET in chemotherapy resistance | Oncogene
c-Met inhibitor - Wikipedia
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
